Kirsten Craven

LC-MS system replacement: Are you ready?

Aug 16, 2024 | Blogs, Pharma, QTRAP / Triple Quad | 0 comments

Read time: 2 minutes

Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?

Let’s break down the process and potential benefits of a regulated laboratory. The biggest challenge is usually the software installation and validation. To streamline this step, the Change Control support plan from SCIEX helps customers who require revalidation of their software to mitigate risk for software and hardware system assessments. Collaborate with us to integrate new software features seamlessly, bolster system security, enhance performance and ensure compatibility.

Is it time … for more reliability?

High system robustness enables analysis of large-scale sample sets

Learn how the robustness of the QTRAP 6500+ system ensures a smooth analysis of gut metabolites in plasma even with a high number of samples, complex matrices and challenging excipients.

Is it time … for more sensitivity?

Highly sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma

Fluticasone propionate, a synthetic glucocorticoid with potent anti-inflammatory activity, requires very sensitive assays to monitor pharmacokinetic parameters due to the very low therapeutic inhaled dose ranges. This need has led us to use large sample volumes. Here, a selective, sensitive and reproducible bioanalytical method was developed for quantitation of fluticasone propionate (LLOQ of 200 fg/mL) in human plasma using the QTRAP 6500 system. Reduced sample volume (500 µL plasma) and a final reconstitution volume of 200 µL for reinjection of samples or repeat analysis chromatography if required in a GLP laboratory.

Is it time … to reduce operational costs?

SCIEX OS software allows you to upgrade to a dry roughing pump configuration, you can expand your productivity and save money at the same time.

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Antibody-drug conjugates (ADCs) are among the most promising—and analytically demanding—modalities in biopharma today. By combining large, heterogeneous antibodies with chemically labile payloads and linkers, ADCs introduce a level of structural complexity that challenges conventional analytical workflows. It also poses the challenge that the very features you need to measure are often the easiest to lose during analysis.

Six benefits of remote support every laboratory should know

Imagine having a tech expert at your fingertips to solve computer issues or a fitness trainer guiding you through workouts from the comfort of your home. In today’s fast-paced world, the ability to provide and receive service and support remotely is no longer a luxury but a necessity. Whether it’s troubleshooting a software issue, repairing a device, offering customer assistance, or enjoying the convenience of telehealth as a private individual, remote capabilities have revolutionized how businesses operate and how individuals get help

The costly consequences of unplanned downtime

Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments